HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Erkut Bahceci Selected Research

gilteritinib

12/2022Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.
1/2021The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
11/2020Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
10/2020Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
10/2019Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
10/2018Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Erkut Bahceci Research Topics

Disease

7Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2022 - 01/2018
3Neoplasms (Cancer)
03/2021 - 01/2009
3Graft vs Host Disease (Graft-Versus-Host Disease)
12/2013 - 09/2003
2Thrombocytopenia (Thrombopenia)
10/2019 - 10/2018
2Lymphoma (Lymphomas)
01/2009 - 10/2006
1Aneuploidy (Aneuploid)
12/2022
1Cataract (Cataracts)
03/2021
1Febrile Neutropenia
10/2019
1Anemia
10/2019
1Syncope (Fainting)
10/2018
1Tumor Lysis Syndrome
10/2018
1Residual Neoplasm
01/2018
1Fatigue
01/2017
1Neuroblastoma
03/2016
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2016
1Exanthema (Rash)
03/2016
1Leukemia
10/2006
1Cytopenia
08/2002
1Bone Marrow Failure Disorders
08/2002
1Body Weight (Weight, Body)
08/2002
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
08/2002

Drug/Important Bio-Agent (IBA)

6gilteritinibIBA
12/2022 - 10/2018
4fms-Like Tyrosine Kinase 3IBA
11/2020 - 01/2018
2Alanine Transaminase (SGPT)IBA
03/2021 - 01/2017
2Anaplastic Lymphoma KinaseIBA
03/2021 - 03/2016
2ASP3026IBA
03/2021 - 03/2016
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
03/2021 - 01/2017
2Tyrosine Kinase InhibitorsIBA
11/2020 - 10/2020
2Messenger RNA (mRNA)IBA
01/2009 - 10/2006
1Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
12/2022
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
12/2022
1ChromatinIBA
12/2022
1Proteins (Proteins, Gene)FDA Link
03/2021
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
11/2020
1AmylasesFDA Link
10/2018
1Creatine Kinase (Creatine Phosphokinase)IBA
10/2018
1Pharmaceutical PreparationsIBA
10/2018
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
10/2018
1CrizotinibIBA
03/2016
1Transaminases (Aminotransferases)IBA
03/2016
1plerixaforFDA Link
12/2013
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
12/2013
1Adrenal Cortex Hormones (Corticosteroids)IBA
07/2009
1Surface Antigens (Surface Antigen)IBA
10/2006
1Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA
08/2002

Therapy/Procedure

4Therapeutics
01/2021 - 01/2009
2Drug Therapy (Chemotherapy)
12/2022 - 10/2019
1Duration of Therapy
10/2019
1Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
09/2003
1Erythrocyte Transfusion
08/2002